AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Chemomab Announces Phase 2 Trial Results for Nebokitug in Primary Sclerosing Cholangitis Published in Gastroenterology Journal
ByAinvest
Tuesday, Dec 2, 2025 8:02 am ET1min read
Chemomab Therapeutics announced that its Phase 2 SPRING trial results for nebokitug in primary sclerosing cholangitis (PSC) were published in the American Journal of Gastroenterology. Nebokitug was found to be safe and well-tolerated in patients with PSC, with numerical improvements in biomarkers for inflammation and fibrosis. The study's authors conclude that the promising data support further evaluation of nebokitug in a Phase 3 clinical trial.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Incβs editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
ο»Ώ
No comments yet